DK2583978T3 - Forebyggelse og behandling af synucleinopatiske og amyloidogene sygdomme - Google Patents

Forebyggelse og behandling af synucleinopatiske og amyloidogene sygdomme Download PDF

Info

Publication number
DK2583978T3
DK2583978T3 DK12188562.8T DK12188562T DK2583978T3 DK 2583978 T3 DK2583978 T3 DK 2583978T3 DK 12188562 T DK12188562 T DK 12188562T DK 2583978 T3 DK2583978 T3 DK 2583978T3
Authority
DK
Denmark
Prior art keywords
antibody
alpha
synuclein
antibodies
human
Prior art date
Application number
DK12188562.8T
Other languages
English (en)
Inventor
Dale B Schenk
Eliezer Masliah
Tamie J Chilcote
Edward Rockenstein
Kate Dora Games
Manuel J Buttini
Original Assignee
Prothena Biosciences Ltd
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/710,248 external-priority patent/US9034337B2/en
Priority claimed from US11/697,646 external-priority patent/US20080014194A1/en
Application filed by Prothena Biosciences Ltd, Univ California filed Critical Prothena Biosciences Ltd
Priority claimed from EP08725981.8A external-priority patent/EP2118300B1/en
Application granted granted Critical
Publication of DK2583978T3 publication Critical patent/DK2583978T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Claims (10)

1. Monoklonalt anti-synuclein-antistof 1H7, eller humaniseret eller kimært 1H7, hvor antistoffet 1H7 er produceret af hybridom JH17.1 H7.4.24.34 deponeret under ATCC-accessionsnummer PTA-8220.
2. Monoklonalt anti-synuclein-antistof ifølge krav 1, hvilket antistof er humaniseret 1H7 produceret ved podning af CDR’er af 1H7 på humane framework- og konstante regioner, hvor udvalgte framework-rester fra den humane variable region eventuelt er substitueret, som følger: en udvalgt framework-rest fra den humane variable region er substitueret med en tilsvarende framework-aminosyre fra 1 H7-museantistoffet, når aminosyren (1) ikke-kovalent binder antigen direkte, (2) støder op til en CDR-region, (3) interagerer på anden måde med en CDR-region eller (4) deltager i VL-VH-interfacet; eller en human framework-aminosyre, der er usædvanlig for et humant immunglobulin ved denne position, er substitueret med en aminosyre fra den tilsvarende position af musedonorantistoffet eller fra den tilsvarende position af et mere typisk humant immunglobulin.
3. Fremgangsmåde til humanisering af monoklonalt antistof 1H7 produceret af hybridomet deponeret under ATCC-accessionsnummer PTA-8220, hvilken fremgangsmåde omfatter: bestemmelse af aminosyresekvensen fra CDR-regioner af det monoklonale antistof; udvælgelse af et acceptorantistof og fremstilling af et humaniseret antistof omfattende CDR’erne fra det monoklonale antistof og framework fra den variable region af acceptorantistoffet.
4. Fremgangsmåde til fremstilling af en kimær form af monoklonalt antistof 1H7 produceret af hybridomet deponeret under ATCC-accessionsnummer PTA-8220, hvilken fremgangsmåde omfatter: bestemmelse af aminosyresekvensen fra de variable let- og tungkæde-regioner af det monoklonale antistof; udvælgelse af en konstant tung- og letkæde-region; fremstilling af et kimært antistof opfattende en letkæde omfattende den variable letkæde-region kondenseret til den konstante letkæde-region, og en tungkæde omfattende den variable tungkæde-region kondenseret til den konstante tungkæde-region.
5. Antistof ifølge krav 1 eller krav 2 til anvendelse i profylakse eller behandling af en sygdom kendetegnet ved Lewy-legemer eller alpha-synuclein aggregering i hjernen.
6. Antistof ifølge krav 5 til anvendelse ifølge dette krav, hvor sygdommen er Parkinsons sygdom.
7. Antistof ifølge krav 5 eller krav 6 til anvendelse ifølge dette krav, hvor antistoffet er af human lgG1-isotype.
8. Antistof ifølge et hvilket som helst af kravene 5 til 7 til anvendelse ifølge dette krav, hvor antistoffet administreres i talrige doseringer over mindst seks måneder.
9. Antistof ifølge et hvilket som helst af kravene 5 til 7 til anvendelse ifølge dette krav, hvor antistoffet administreres ad en perifer vej.
10. Celle af hybridom JH17.1H7.4.24.34 deponeret under ATCC-accessionsnummer PTA-8220.
DK12188562.8T 2007-02-23 2008-02-22 Forebyggelse og behandling af synucleinopatiske og amyloidogene sygdomme DK2583978T3 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US11/710,248 US9034337B2 (en) 2003-10-31 2007-02-23 Treatment and delay of outset of synucleinopathic and amyloidogenic disease
US11/697,646 US20080014194A1 (en) 2003-10-31 2007-04-06 Prevention and Treatment of Synucleinopathic and Amyloidogenic Disease
US98472107P 2007-11-01 2007-11-01
EP08725981.8A EP2118300B1 (en) 2007-02-23 2008-02-22 Prevention and treatment of synucleinopathic and amyloidogenic disease

Publications (1)

Publication Number Publication Date
DK2583978T3 true DK2583978T3 (da) 2016-05-17

Family

ID=55959738

Family Applications (1)

Application Number Title Priority Date Filing Date
DK12188562.8T DK2583978T3 (da) 2007-02-23 2008-02-22 Forebyggelse og behandling af synucleinopatiske og amyloidogene sygdomme

Country Status (1)

Country Link
DK (1) DK2583978T3 (da)

Similar Documents

Publication Publication Date Title
US20210032318A1 (en) Prevention and treatment of synucleinopathic and amyloidogenic disease
EP2583978B1 (en) Prevention and treatment of synucleinopathic and amyloidogenic disease
DK1793855T3 (da) Forebyggelse og behandling af synukleinopatisk og amyloidogenisk sygdom
US7919088B2 (en) Treatment and delay of onset of synucleinopathic and amyloidogenic disease
US9034337B2 (en) Treatment and delay of outset of synucleinopathic and amyloidogenic disease
CA2616047C (en) Prevention and treatment of synucleinopathic and amyloidogenic disease
EP1594969B1 (en) Active immunization to generate antibodies to soluble a-beta
DK2118300T3 (da) Forebyggelse og behandlng af synukleinopatisk og amyloidogen sygdom
US20160184416A1 (en) Prevention and Treatment of Synucleinopathic and Amyloidogenic Disease
US20240254211A1 (en) Prevention and treatment of synucleinopathic and amyloidogenic disease
HK1260628A1 (en) Prevention and treatment of synucleinopathic and amyloidogenic disease
HK1228767B (en) Prevention and treatment of synucleinopathic and amyloidogenic disease
HK1228767A1 (en) Prevention and treatment of synucleinopathic and amyloidogenic disease
HK1184169B (en) Prevention and treatment of synucleinopathic and amyloidogenic disease
HK1138622B (en) Prevention and treatment of synucleinopathic and amyloidogenic disease